基本信息
浏览量:4
职业迁徙
个人简介
Research interests
Professor Vandenberg's research interests have focused on understanding how neurotransmitter transporters work. These proteins play key roles in regulating neurotransmission in the brain and are also the targets of a number of theraputic drugs and drugs of abuse. The laboratory uses a number of state-of-the-art molecular and biophysical techniques to address questions as to how these proteins bind neurotransmitters, how drugs interact with and modulate transporters and how these processes go wrong in disease states, such as Chronic Pain, Schizophrenia and Ischemia following a stroke.
A major focus of our work is on the development of novel compounds that inhibit glycine transporters. These compounds represent a new class of transport inhibitors and show considerable potential as analgesics for the treatment of chronic pain. Rob Vandenberg leads a multi-pronged approach to the drug development program funded by the NHMRC and NIH (USA) which includes collaborators at USYD (Mac Christie, Sarasa Mohammadi), UTS (Tristan Rawling), ANU (Megan O'Mara), Albany College of Pharmacy in New York (Chris Cioffi) and the University of Copenhagen (Claus Loland). Our work encompasses drug design, medicinal chemistry, understanding mechanisms of inhibition, structural biology, molecular dynamics simulations, synaptic physiology and behavioural pharmacology. We are also investigating the pharmacokinetic properties of these compounds with the aim of developing drugs that can be used in the clinic.
Professor Vandenberg's research interests have focused on understanding how neurotransmitter transporters work. These proteins play key roles in regulating neurotransmission in the brain and are also the targets of a number of theraputic drugs and drugs of abuse. The laboratory uses a number of state-of-the-art molecular and biophysical techniques to address questions as to how these proteins bind neurotransmitters, how drugs interact with and modulate transporters and how these processes go wrong in disease states, such as Chronic Pain, Schizophrenia and Ischemia following a stroke.
A major focus of our work is on the development of novel compounds that inhibit glycine transporters. These compounds represent a new class of transport inhibitors and show considerable potential as analgesics for the treatment of chronic pain. Rob Vandenberg leads a multi-pronged approach to the drug development program funded by the NHMRC and NIH (USA) which includes collaborators at USYD (Mac Christie, Sarasa Mohammadi), UTS (Tristan Rawling), ANU (Megan O'Mara), Albany College of Pharmacy in New York (Chris Cioffi) and the University of Copenhagen (Claus Loland). Our work encompasses drug design, medicinal chemistry, understanding mechanisms of inhibition, structural biology, molecular dynamics simulations, synaptic physiology and behavioural pharmacology. We are also investigating the pharmacokinetic properties of these compounds with the aim of developing drugs that can be used in the clinic.
研究兴趣
论文共 111 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ryan Cantwell Chater, Ada S. Quinn,Katie Wilson,Zachary J. Frangos, Patrick Sutton,Srinivasan Jayakumar, Christopher L. Cioffi, Megan L. O'Mara,Robert J. Vandenberg
Journal of neurochemistry (2023)
ACS chemical neuroscienceno. 15 (2023): 2634-2647
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Julian M. Peiser-Oliver,Sally Evans,David J. Adams,Macdonald J. Christie,Robert J. Vandenberg,Sarasa A. Mohammadi
FRONTIERS IN PHARMACOLOGY (2022)
Journal of Pharmacology and Experimental Therapeuticsno. 3 (2022): 246-255
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn